$派格生物医药-B(_老虎社区_美港股上老虎

$派格生物医药-B(02565)$ 市场分析认为，公司已形成“PB-119（已获批周制剂）与CR059（在研月级制剂）”的产品组合，实现了从“周”到“月”给药周期的技术覆盖，构筑了长期竞争壁垒

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":542103009751400,"tweetId":"542103009751400","gmtCreate":1773374861417,"gmtModify":1773374863545,"author":{"id":4203843771083212,"idStr":"4203843771083212","authorId":4203843771083212,"authorIdStr":"4203843771083212","name":"乐山大佛笑哈哈","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 市场分析认为，公司已形成“PB-119（已获批周制剂）与CR059（在研月级制剂）”的产品组合，实现了从“周”到“月”给药周期的技术覆盖，构筑了长期竞争壁垒</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 市场分析认为，公司已形成“PB-119（已获批周制剂）与CR059（在研月级制剂）”的产品组合，实现了从“周”到“月”给药周期的技术覆盖，构筑了长期竞争壁垒</p></body></html>","text":"$派格生物医药-B(02565)$ 市场分析认为，公司已形成“PB-119（已获批周制剂）与CR059（在研月级制剂）”的产品组合，实现了从“周”到“月”给药周期的技术覆盖，构筑了长期竞争壁垒","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/542103009751400","repostId":0,"isVote":1,"tweetType":1,"viewCount":146,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02565"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":155,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}